Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis

Shmidt T.E.

doi:https://doi.org/10.17116/jnevro2017117111140-145

Shmidt T.E.

Kafedra nervnykh bolezneĭ Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, Moskva

Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis

Authors:

Shmidt T.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(11): 140‑145

DOI: 10.17116/jnevro2017117111140-145

Read: 9146 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Shmidt TE. Dimethyl fumarate (tecfidera) is the first line treatment choice in patients with remitting multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(11):140‑145. (In Russ.)
https://doi.org/10.17116/jnevro2017117111140-145

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Surgical treatment of secondary trigeminal neuralgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):203-209

Quality of life of patients with multiple sclerosis in the Smolensk region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):36-40

Hormonal contraception methods and multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30

Epidemiology of multiple sclerosis in the city of Novosibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127

Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68

A clinical case of X-linked adrenoleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107

Prospects for treating Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):54-60

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Artificial intelligence capabilities in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21

Molecular mechanisms of acute disseminated encephalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11

Abstract:

Dimethyl fumarate (DMF) is a new oral option for disease-modifying therapy (DMT) in patients with remitting multiple sclerosis as a first line treatment. The results of international randomized studies comparing DMF with placebo and other DMTs are presented. DMF is a DMT with promised efficacy and favorable safety profile that could be a treatment option for patients with suboptimal response for other first line DMTs and used as initial therapy for treatment-naive patients with unfavorable prognostic factors.

Keywords:

multiple sclerosis

dimethyl fumarate

disease-modifying therapy

glatiramer acetate

interferon β

fingolimod

teriflunomide

natalizimab

progressive multifocal leukoencephalopathy

Authors:

Shmidt T.E.

Kafedra nervnykh bolezneĭ Pervogo Moskovskogo gosudarstvennogo meditsinskogo universiteta im. I.M. Sechenova, Moskva

Close metadata

References:

Rieckman P. Inflamation and neurodegenaration: the role of these dual players in MS. Therapeutic strategies in MS: from neuroprotection to long term efficacy. 2004;5-10.
Shmidt TE, Yakhno NN. Rasseyannyi skleroz. M.: MED press-inform; 2016. (In Russ.)
Zhuchenko TD, Shmidt TE. Kopakson — novoe sredstvo dlya lecheniya rasseyannogo skleroza. Vestn prakt nevr. 1998;4;194-196. (In Russ.)
Burks J. Interferon beta-1b in MS. Expert Review of Neurotherapeutics. 2005;5(2):153-164.
Correale J. Personalized Treatment in Multiple Sclerosis. Curr Neurol Neurosci Rep. 2011 Dec;11(6):523-525. https://doi.org/10.1007/s11910-011-0218-7
Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. Neutralising antibodies to interferon beta in multiple sclerosis. Expert panel report. J Neurol. 2007;254(7):827-837. https://doi.org/10.1007/s00415-006-0486-3
Coyle P. Switching algorithms: from one immunomodulatory agent to another. Journal of Neurology. 2008;255(suppl 1):44-50. https://doi.org/10.1007/s00415-008-1007-3
Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine. 2006;354(9):899-910. https://doi.org/10.1056/NEJMoa044397
Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine. 2010;362(5): 387-401. https://doi.org/10.1056/nejmoa0909494
Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseier BC; GAP Study Group. The Global Adherence Project (GAP): a multicenter observational study of adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. European Journal of Neurology. 2011;18(1):69-77. https://doi.org/10.1111/j.1468-1331.2010.03110.x
Popova EV, Khachanova NV, Lashch NYu Orlova EV, Boyko AN. Dimetilfumarat: novyi tabletirovannyi preparat dlya lecheniya rasseyannogo skleroza. Meditsinskii sovet. 2015;18:74-79. (In Russ.) https://doi.org/10.21518/2079-701X-2015-18-74-79
Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy Journal of Neurology. 2004;251:261-268. https://doi.org/10.1007/s00415-004-0348-9
Popova EV, Boiko AN, Orlova EV. Dimethylfumarate in the treatment of relapsing-remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii. 2016;10(2):66-70. (In Russ.) https://doi.org/10.17116/jnevro201611610268-72
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT; DEFINE Study Investigators. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. N Engl J Med. 2012;367(12):1098-1107. https://doi.org/10.1056/NEJMoa1114287
Bar-Or A, Gold R, Kappos L, Arnold DL, Giovannoni G, Selmaj K, O’Gorman J, Stephan M, Dawson KT. Clinical of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. Journal of Neurology. 2013;260:2297-2305. https://doi.org/10.1007/s00415-013-6954-7
Arnold DL, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K, Yang M, Zhang R, Stephan M, Sheikh SI, Dawson KT Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study. Journal of Neurology. 2014;261:1794-1802. https://doi.org/10.1007/s00415-014-7412-x
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. New England Journal of Medicine. 2012;367(12):1087-1097. https://doi.org/10.1056/NEJMoa1206328
Viglietta V, Miller D, Bar-Or A, Phillips JT, Arnold DL, Selmaj K, Kita M, Hutchinson M, Yang M, Zhang R, Dawson KT, Sheikh SI, Fox RJ, Gold R. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol. 2015;2(2):103-118. https://doi.org/10.1002/acn3.148
Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Multiple sclerosis journal. 2017;23(2):253-265. https://doi.org/10.1177/1352458516649037
Couto E, Hamidi V, Ringerike T, Odgaard-Jensen J, Harboe I, Klemp M. Medicines used for Multiple Sclerosis — A Health Technology. Norwegian Institute of Public Health. Oslo. 2016
Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza J. 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. In Clinical Measures and Impact on Patient-Reported Outcomes of Delayed-release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients After Suboptimal Response to Glatiramer Acetate: Analysis of the 12-Month RESPOND Study. London, UK: 14-17 September, 2016.
Spelman T, Kalincik T, Trojano M, Grand’Maison F, Izquierdo G, Havrdova E, Horakova D, Lugaresi A, Duquette P, Grammond P, Hupperts R, Lechner-Scott J, Granella F, Petersen T, Terzi M, Pucci E, Sola P, Van Pesch V, Iuliano G, Oreja-Guevara C, Boz C, Bergamaschi R, Slee M, Butzkueven H, on behalf of the MSBase Investigators 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide. London, UK: [s.n.]. 14—17 September, 2016
Nicholas J, Boster A, Wu N. Comparative Effectiveness of Delayed-Release Dimethyl Fumarate versus Fingolimod and Teriflunomide for Risk of Relapse. P6.375. Presented at American Academy of Neurology. 2017 — 69th Annual Meeting I April 22-28, 2017 I Boston, MA.
Fogarty E, Schmitz S, Tubridy N, Walsh C, Barry M. Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: Systematic review and network meta-analysis. Mult Scler Relat Disord. 2016;9:23-30. https://doi.org/10.1016/j.msard.2016.06.001
Alifirova VM, Boiko AN, Vlasov YV, Davydovskaya MV, Zakharova MN, Malkova NA, Popova EV, Sivertseva SA, Spirin NN, Khachanova NV, Shmidt ТЕ. Clinical guidelines for the use of dimethyl fumarate in relapsing-remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117:1:97-102. (In Russ.) https://doi.org/10.17116/jnevro20171171197-102